SKA-31 is primarily studied for its potential therapeutic applications in cardiovascular diseases. It functions as a potent activator of intermediate-conductance calcium-activated potassium channels (IK channels) and small-conductance calcium-activated potassium channels (SK channels). By activating these channels, SKA-31 helps to regulate vascular tone and blood pressure, making it a promising candidate for treating hypertension and other vascular disorders. Additionally, its ability to modulate endothelial function suggests potential benefits in improving blood flow and reducing the risk of atherosclerosis. Research is also exploring its role in mitigating ischemia-reperfusion injury, which occurs when blood supply returns to tissue after a period of lack of oxygen. Furthermore, SKA-31 is being investigated for its neuroprotective effects, particularly in conditions like stroke, where it may help reduce neuronal damage by maintaining cellular homeostasis. Its applications extend to studying smooth muscle physiology and its role in various pathological conditions, providing insights into novel treatment strategies.